

EDITORIAL



Sanofi-Cell Research outstanding paper award of 2022

© The Author(s) under exclusive licence to Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences 2023, corrected publication 2023

Cell Research (2023) 33:891; <https://doi.org/10.1038/s41422-023-00904-1>

We are pleased to announce the winners of the 2022 Sanofi-Cell Research Outstanding Research Article Award: Drs Yu Lan, Fuchou Tang and Bing Liu for their paper entitled “Heterogeneity in endothelial cells and widespread venous arterialization during early vascular development in mammals”;¹ Drs Penghui Zhou, Zhixiang Zuo, Wende Li, Zhenjiang Liu, Xiaoshi Zhang and Peirong Ding for their paper entitled “Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response”;² and Drs Chun-Qing Song and En-Zhi Shen for their paper entitled “CRISPR FISHer enables high-sensitivity imaging of nonrepetitive DNA in living cells through phase separation-mediated signal amplification”.³ Each award consists of a prize of ¥40,000 sponsored by Sanofi.

The developmental origin of arterial endothelial cells throughout an entire embryo was not elucidated before. In the first award-winning research article published in the April 2022 issue, by combining single-cell transcriptomic profiling and mouse lineage tracing, Drs Yu Lan, Fuchou Tang, Bing Liu and colleagues demonstrated widespread venous arterialization during mammalian early vascular development.¹

In the second award-winning research article, published in the June 2022 issue, Drs Penghui Zhou, Zhixiang Zuo, Wende Li, Zhenjiang Liu, Xiaoshi Zhang, Peirong Ding and colleagues showed that naturally occurring tumor antigen-specific T (Tas)

cells can be harnessed to develop personalized T-cell receptor (TCR)-T cells. Experiments with the TCR-T cells expressing TCRs from the patient’s own Tas cells have shown encouraging therapeutic effects in patient-derived xenograft models.² These findings offer a promising agent for future cancer immunotherapy.

In the third award-winning research article, published in the November 2022 issue, Drs Chun-Qing Song, En-Zhi Shen and their colleagues introduced a novel DNA imaging strategy, termed CRISPR-mediated fluorescence in situ hybridization amplifier (CRISPR FISHer), based on engineered sgRNA and trimeric protein motif-triggered, phase separation-mediated signal amplification. With a single sgRNA, CRISPR FISHer tracks real-time dynamics of endogenous nonrepetitive DNA sequences in living cells.³

Please join us to congratulate Drs Yu Lan, Fuchou Tang, Bing Liu, Penghui Zhou, Zhixiang Zuo, Wende Li, Zhenjiang Liu, Xiaoshi Zhang, Peirong Ding, Chun-Qing Song, En-Zhi Shen and their colleagues on their winning of the 2022 Sanofi-Cell Research Outstanding Paper Award.

Cell Research Editorial Team¹


¹Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences, Shanghai, China.

REFERENCES

- Hou, S. et al. *Cell Res.* **32**, 333–348 (2022).
- He, J. et al. *Cell Res.* **32**, 530–542 (2022).
- Lyu, X. Y. et al. *Cell Res.* **32**, 969–981 (2022).



Dr Yu Lan



Dr Fuchou Tang



Dr Bing Liu



Dr Chun-Qing Song



Dr En-Zhi Shen



Dr Penghui Zhou



Dr Zhixiang Zuo



Dr Wende Li



Dr Zhenjiang Liu



Dr Xiaoshi Zhang



Dr Peirong Ding